Venobotic
Automated CVAD Blood Sampling and Flushing for Safer Central-line Care
Company Overview
Snapshot
Founded in March 2025 by Michal Singer, Venobotic operates with 1–10 employees. The company has secured funding across one round from one investor, eHealth Ventures, to advance its automated medical device platform.
Business overview
Venobotic is a Health Tech & Life Sciences company specializing in Medical Devices and Medical Treatment & Therapeutics. The company develops LineGuard, an automated medical device platform designed for blood sampling, flushing, and disinfection through Central Venous Access Devices. This system aims to standardize workflow, reduce contamination risks, and improve protocol consistency in hospitals, oncology units, ICUs, post-operative wards, community clinics, home infusion, and palliative-care settings. Venobotic primarily serves the Healthcare & Life Sciences sector, targeting laboratories and providers in markets such as Israel and the United States.
Log in to access full profile ›Company Intelligence Q&A
- When was Venobotic founded?
- Venobotic was founded in March 2025.
- Who is a co-founder of Venobotic?
- Michal Singer is a co-founder and Scientific Advisor at Venobotic.
- What is Venobotic's primary product?
- Venobotic's primary product is LineGuard, an automated medical device platform for CVAD blood sampling, flushing, and disinfection.
- What markets does Venobotic serve?
- Venobotic serves healthcare providers and laboratories in geomarkets including Israel and the United States.